PPSV23 + Act-HIB

PPSV23 + Act-HIB is a vaccine combination investigated by Uppsala University for the prevention of post-traumatic meningitis in patients following neurotrauma or neurosurgery, such as those with basilar skull fractures. The combination consists of two distinct vaccines: PPSV23 (Pneumovax 23), a 23-valent pneumococcal polysaccharide vaccine that induces a T-cell-independent immune response against *Streptococcus pneumoniae*, and Act-HIB, a conjugate vaccine that induces a T-cell-dependent immune response against *Haemophilus influenzae* type b (Hib). The clinical study (NCT02806284) specifically evaluated the timing of administration (early, within 10 days, versus late, at least 3 weeks after injury) to determine the optimal window for mounting an effective immune response in patients with compromised skull integrity who are at high risk for bacterial meningitis.

Brand names

Pneumovax 23Pneumovax23Pneumovax-23Act-HIB

Other names

23-valent pneumococcal polysaccharide vaccine + Hib conjugate vaccinePPSV23 + Act-HIB-Uppsala University-meningitisPneumococci and Hib Vaccination